NANO.PA
Price:
$3.74
Market Cap:
$176.20M
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.[Read more]
Industry
Biotechnology
IPO Date
2012-10-29
Stock Exchange
EURONEXT
Ticker
NANO.PA
According to Nanobiotix S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -5.05. This represents a change of 90.49% compared to the average of -2.65 of the last 4 quarters.
The mean historical PE Ratio of Nanobiotix S.A. over the last ten years is -9.14. The current -5.05 PE Ratio has changed 5.43% with respect to the historical average. Over the past ten years (40 quarters), NANO.PA's PE Ratio was at its highest in in the December 2022 quarter at -1.03. The PE Ratio was at its lowest in in the June 2014 quarter at -12.76.
Average
-9.14
Median
-8.77
Minimum
-22.52
Maximum
-2.21
Discovering the peaks and valleys of Nanobiotix S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 223.59%
Maximum Annual PE Ratio = -2.21
Minimum Annual Increase = -59.05%
Minimum Annual PE Ratio = -22.52
Year | PE Ratio | Change |
---|---|---|
2023 | -6.15 | 177.97% |
2022 | -2.21 | -59.05% |
2021 | -5.40 | -46.08% |
2020 | -10.02 | 184.80% |
2019 | -3.52 | -53.26% |
2018 | -7.53 | -25.09% |
2017 | -10.05 | -6.81% |
2016 | -10.78 | -18.31% |
2015 | -13.20 | -41.39% |
2014 | -22.52 | 223.59% |
The current PE Ratio of Nanobiotix S.A. (NANO.PA) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.59
5-year avg
-5.46
10-year avg
-9.14
Nanobiotix S.A.’s PE Ratio is less than Genfit S.A. (171.30), less than Innate Pharma S.A. (-3.84), less than ERYTECH Pharma S.A. (-0.49), less than Cellectis S.A. (-2.13), less than Adocia SA (-3.18),
Company | PE Ratio | Market cap |
---|---|---|
171.30 | $243.39M | |
-3.84 | $130.81M | |
-0.49 | $48.66M | |
-2.13 | $129.77M | |
-3.18 | $123.23M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nanobiotix S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nanobiotix S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Nanobiotix S.A.'s PE Ratio?
How is the PE Ratio calculated for Nanobiotix S.A. (NANO.PA)?
What is the highest PE Ratio for Nanobiotix S.A. (NANO.PA)?
What is the 3-year average PE Ratio for Nanobiotix S.A. (NANO.PA)?
What is the 5-year average PE Ratio for Nanobiotix S.A. (NANO.PA)?
How does the current PE Ratio for Nanobiotix S.A. (NANO.PA) compare to its historical average?